Tempus AI Inc. TEM shares are up on Thursday as Mizuho initiated coverage on the health care-focused artificial intelligence firm. Analyst Bradley Bowers started coverage with an Outperform rating and ...
Tempus AI TEM rose on Wednesday after the company unveiled its new HRD-RNA algorithm, an AI-driven tool designed to improve detection of homologous recombination deficiency (HRD) in tumors. The ...
In a statement today, HRD Corp chief executive Shamir Aziz said the move highlights the organisation’s commitment to raising governance standards and ensuring that national workforce development ...
How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, ...
HRD is proud to reveal this year's HRD Global 100 for 2024. An annual event, the report highlights leaders in HR selected for their outstanding commitment to their companies and their people over the ...
Rucaparib maintenance therapy provided consistent benefits across all subgroups of patients grouped by prognostic factors of their homologous recombination deficiency-negative ovarian cancer tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results